Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse

Journal of Rheumatology

Volumn 26, Issue 1, 1999, Pages 60-67

  Van Lopik, Thea ^a   Bijl, Marc ^b   Hart, Margreet ^b   Boeije, Leonie ^b   Gesner, Tom ^b   Creasy, Abla A ^b   Kallenberg, Cees G M ^b   Aarden, Lucien A ^b   Smeenk, Ruud J T ^b  

^a CENTRAL LABORATORY   (Netherlands)

^b NONE

Author keywords

Apoptosis; CD95; Monoclonal antibodies; Soluble Fas; Systemic lupus erythematosus

Indexed keywords

FAS ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; PLASMA; PRIORITY JOURNAL; RELAPSE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIGENS, CD95; BIOLOGICAL MARKERS; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECURRENCE; RISK FACTORS;

EID: 0032917249     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Lynch DH, Watson ML, Alderson MR, et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994;1:131-6.
2. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985;37:269-390.
3. Nagata S, Suda T, Fas and Fas ligand: Ipr and gld mutations. Immunol Today 1995;16:39-43.
4. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62.
5. Itoh N, Yoneharu S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
6. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-29.
7. Debatin KM, Goldman CK, Waldmann TA, Krammer PH. APO-1 induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood 1993;81:2972-7.
8. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
9. Möller P, Henne C, Leithäuser F, et al. Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood 1993;81:2067-75.
10. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
11. Watanabe-Fukunaga R, Brannan CI, Itoh M, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992;148:1274-9.
12. Giese T, Davidson WF. Evidence for early onset, polyclonal activation of T cell subsets in mice homozygous for Ipr. J Immunol 1992;149:3097-106.
13. Singer GG, Abbas AK. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994;1:365-71.
14. Crispe IN. Fatal interactions: Fas-induced apoptosis of mature T-cells. Immunity 1994;1:347-9.
15. Alderson MR, Tough TW, Davis-Smith T, et al. Fas-ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-7.
16. Brunner T, Mogil RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995;373:441-1.
17. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-41.
18. Ju ST, Panka DJ, Cui H, et al. Fas/(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
19. Miyawaki T, Uehara T, Nibu R, et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992;149:3653-758.
20. Itoh N, Tsujimoto Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 1993;151:621-7.
21. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T-cells. Int Immunol 1993;5:625-30.
22. Henkart PA. ICE family proteases: mediators of all apoptotic cell death? Immunity 1996;4:195-201.
23. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-27.
24. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF-receptor induced cell death. Cell 1996;85:803-15.
25. Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/CED-3 protease nomenclature. Cell 1996;87:171.
26. Mysler E, Bini P, Drappa J, et al. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994;93:1029-34.
27. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. An N-terminal domain shared by Fas/APO-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996;156:4622-30.
28. Jodo S, Kobayashi S, Kayagaki N, et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus and other autoimmune diseases. Clin Exp Immunol 1997;107:89-95.
29. Tokano Y, Miyake S, Kayagaki N, et al. Soluble Fas molecule in the serum of patients with systemic lupus erythematosus. J Clin Immunol 1996;16:261-5.
30. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997;40:1126-9.
31. Rose LM, Latchman DS, Isenberg DA. Elevated soluble fas production in SLE correlates with HLA status not with disease activity. Lupus 1997;7:717-22.
32. Knipping E, Krammer PH, Onel KB, Lehman TJ, Mysler E, Elkon KB. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995;38:1735-7.
33. Goel N, Ulrich DT, St. Clair EW, Fleming JA, Lynch DH, Seldin MF. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune diseases. Arthritis Rheum 1995;38:1738-43.
34. Kohno T, Brewer MT, Baker SL, et al. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 1990;87:8331-5.
35. Digel W, Porzsolt F, Schmid M, Herrmann F, Lesslauer W, Brockhaus M. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest 1992;89:1690-3.
36. Fukunaga R, Seto Y, Mizushima, Nagata S. Three different mRNAs encoding human granulocy te colony-stimulating factor receptor. Proc Natl Acad Sci USA 1990;8:8702-6.
37. Swaak AJG, Aarden LA, Statius van Eps LW, Feltkamp TE, Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erylhematosus. Arthritis Rheum 1979;22:226-35.
38. Grussenmeyer T, Scheidtmann KH, Hutchinson MA, Eckhart W, Walter G. Complexes of polyomavirus medium T antigen and cellular peptides. Proc Natl Acad Sci USA 1985;82:7952-4.
39. Munemitsu S, Innis MA, Clark R, McCormick F, Ullrich A, Polakis P. Molecular cloning and expression of a G25K cDNA, the human homolog of the yeast cell cycle gene CDD42. Moll Cell Biol 1990;10:5977-82.
40. Kitts PA, Ayres MD, Possee RD. Linearization of baculovirus DNA enhances the recovery of recombinant virus expression vectors. Nucleic Acids Res 1990;19:5667-72.
41. Smith GE, Summers MD, Fraser MJ. Production of human beta interferon in insect cells infected with a baculovirus expression vector. Moll Cell Biol 1983;3:2156-65.
42. Helle M, Boeije L, de Groot E, de Vos A, Aarden L. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991;138:47-56.
43. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
44. Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG. Levels of soluble VCAM-1, soluble ICAM-1, soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE): a long term prospective study. Clin Exp Immunol 1994;97:439-44.
45. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995;345:1595-9.
46. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. The committee on prognosis studies in SLE: derivation of the SLEDAI. Arthritis Rheum 1992;35:630-40.
47. Hasunuma T, Kayagaki N, Asahara H, et al. Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 1997;40:80-6.
48. Bansil S, Holtz CR, Cook SD, Rohowsky-Kochan C. Serum sAPO-1/Fas levels in multiple sclerosis. Acta Neurol Scand 1997;95:208-10.
49. Inoue A, Koh CS, Sakai T, et al. Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotrophic virus type-I associated myelopathy. J Neuroimmunol 1997;75:141-6.
50. Jiang JD, Schlesinger M, Sacks H, Mildvan D, Roboz JP, Bekesi JG. Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status. J Clin Immunol 1997;17:185-92.
51. Seishima M, Takemura M, Saito K, Ando K, Noma A. Increased serum soluble Fas (sFas) concentrations in HCV-positive patients with liver cirrhosis. J Hepatol 1997;27:424-5.
52. Nishigaki K, Minatoguchi S, Seishima M, et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 1997;29:1214-20.
53. Okuyama M, Yamaguchi S, Nozaki N, Yamaoka M, Shirakabe M, Tomoike H. Serum levels of soluble forms of Fas molecule in patients with congestive heart failure. Am J Cardiol 1997;79:1698-701.
54. Kamihiri S, Yamada Y, Hiragata Y, et al. Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases. Intern Med 1997;36:166-70.
55. Munker R, Midis G, Owen-Schaub L, Andreff M. Soluble Fas (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia 1996;10:1531-3.
56. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996;56:3870-4.
57. Mogi M, Harada M, Kondo T, et al. The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett 1996;220:195-8.
58. Shinohara K, Ayame H, Yoshida T. Increased levels of soluble Fas antigen in the plasma of the patients with refractory anemia. Int J Hematol 1997;65:413-4.
59. Boehme MW, Waldherr R, Kist A, et al. Kinetics of soluble TNF-receptors and soluble adhesion molecules ICAM-1, E-selectin and VCAM-1 under systemic rhTNF alpha therapy. Eur J Clin Invest 1996;26:404-10.